Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Examining the Use of Non-Invasive Inhaled Nitric Oxide to Reduce Chronic Lung Disease in Premature Newborns

The recruitment status of this study is unknown because the information has not been verified recently.
Verified May 2012 by National Heart, Lung, and Blood Institute (NHLBI).
Recruitment status was  Recruiting
Sponsor:
Information provided by (Responsible Party):
National Heart, Lung, and Blood Institute (NHLBI)
ClinicalTrials.gov Identifier:
NCT00955487
First received: August 6, 2009
Last updated: May 4, 2012
Last verified: May 2012

August 6, 2009
May 4, 2012
January 2007
December 2012   (final data collection date for primary outcome measure)
Combined endpoint of bronchopulmonary dysplasia and mortality [ Time Frame: Week 36 or earlier, if participants are discharged from the hospital ] [ Designated as safety issue: No ]
combined endpoint of bronchopulmonary dysplasia/mortality [ Time Frame: Week 36 or earlier if discharged ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT00955487 on ClinicalTrials.gov Archive Site
Pulmonary hypertension [ Time Frame: Week 36 or earlier, if participants are discharged from the hospital ] [ Designated as safety issue: No ]
Pulmonary hypertension [ Time Frame: Week 36 or earlier if discharged ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
Examining the Use of Non-Invasive Inhaled Nitric Oxide to Reduce Chronic Lung Disease in Premature Newborns
Non-invasive Inhaled Nitric Oxide in Premature Newborns

Bronchopulmonary dysplasia (BPD) is a serious lung condition that affects premature newborns. The condition involves abnormal development of lung tissue and is characterized by inflammation and scarring in the lungs. Treatment with inhaled nitric oxide (iNO) may reduce the incidence of BPD and another commonly associated condition called pulmonary hypertension, which is high blood pressure in the vessels carrying blood to the lungs.. This study will determine if early treatment with low-dose iNO reduces the incidence of BPD, pulmonary hypertension, and death in premature newborns.

BPD is a serious lung condition that primarily affects premature newborns and newborns with low birth weights. iNO has been proven to be a safe and effective treatment for pulmonary hypertension and hypoxemic respiratory failure—both of which are abnormal lung conditions—in full-term newborns. However, in babies born prematurely, the effects of iNO on lung function are not well defined. Also, previous studies have mainly examined whether iNO reduces the incidence of BPD in newborns who are on mechanical ventilation. However, intubation and mechanical ventilation of premature newborns is now increasingly being avoided, and non-invasive support, including the use of nasal continuous positive airway pressure (NCPAP), is being used. Early treatment with low-dose iNO may reduce the incidence of BPD in premature newborns who do not require mechanical ventilation and intubation after delivery. The purpose of this study is to determine if low-dose, non-invasive iNO reduces the risk of BPD, pulmonary hypertension, and death in premature newborns who do not require mechanical ventilation.

This study will enroll premature newborns who require extra oxygen but do not require intubation or mechanical ventilation for respiratory failure in the first 72 hours of life. Participants will be randomly assigned to receive low-dose, non-invasive iNO or nitrogen (placebo) during their hospital stay. While hospitalized, participants' heart rate, blood oxygen level breathing rate, blood pressure, and medications will be monitored, and blood collection will occur at various times. Monitoring will continue until participants are 30 weeks corrected gestational age or for at least 14 days if participants are born at 29 weeks or more. All participants will undergo an ultrasound of the head when they are 7 days, 28 days, and 36 weeks of age. They will undergo an echocardiogram, which is an ultrasound of the heart, at 7 and 21 days of age and 4 weeks before the original expected due date. A chest x-ray will be performed before hospital discharge, and a breathing status test will be performed either 4 weeks before participants' original expected due date or before hospital discharge. Follow-up study visits will occur at Years 1 and 2, and will include a physical examination and developmental and behavioral testing. Another echocardiogram will also be performed at the Year 1 visit.

Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Prevention
Bronchopulmonary Dysplasia
  • Drug: Inhaled Nitric Oxide (iNO)
    iNO will be delivered using the iNOVent device to provide 10 ppm proximally (yielding approximately 5 ppm to the posterior pharynx).
  • Drug: Nitrogen (placebo)
    Nitrogen will be delivered using the iNOVent device to provide 10 ppm proximally (yielding approximately 5 ppm to the posterior pharynx).
  • Experimental: Inhaled Nitric Oxide (iNO)
    Participants will receive a low concentration of iNO until they are 30 weeks corrected gestational age or for 14 days if they were born at 29 weeks or more.
    Intervention: Drug: Inhaled Nitric Oxide (iNO)
  • Placebo Comparator: Nitrogen (placebo)
    Participants will receive nitrogen (placebo) while in the hospital.
    Intervention: Drug: Nitrogen (placebo)
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
124
June 2013
December 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Birth weight of 500-1250 grams and gestational age of less than 34 weeks
  • Age at enrollment is less than 72 hours
  • Supplemental oxygen or 21% requirement by nasal cannula or NCPAP only

Exclusion Criteria:

  • Presence of structural heart disease (other than patent ductus arteriosus, atrial septal defect less than 1 cm, or muscular ventricular septal defect less than 2 mm)
  • Presence of lethal congenital anomaly
  • Participating in another concurrent experimental study
  • Requires mechanical ventilation in the first 72 hours of life (patients are not excluded if they are intubated briefly BUT they must be extubated at the time of consent and study entry prior to 72 hours of life)
Both
up to 72 Hours
No
Contact: John Kinsella, MD 303-724-2853 John.Kinsella@ucdenver.edu
Contact: Gary Cutter, PhD 205-975-5048 cutter@prodigy.net
United States
 
NCT00955487
667, 5 P50 HL084923-030001
Yes
National Heart, Lung, and Blood Institute (NHLBI)
National Heart, Lung, and Blood Institute (NHLBI)
Not Provided
Principal Investigator: John Kinsella, MD Chidlren's Hospital and University of Colorado Hospital
National Heart, Lung, and Blood Institute (NHLBI)
May 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP